Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Senate Finance Committee Inquires Into Manufacturer Medicaid Best Price Calculations

This article was originally published in The Pink Sheet Daily

Executive Summary

Nineteen drug manufacturers are asked to submit information and documents on use of the nominal price exception in calculating Medicaid rebates. The committee may consider “refinements” to the existing statutory language.

You may also be interested in...



GSK's Lost Quarter: $3 Billion DoJ Settlement Far Outstrips Net Profit

If approved, the settlement would set a new record for the pharmaceutical industry in its dealings with the federal government, but would be covered by the firm's existing reserves.

GSK's Lost Quarter: $3 Billion DoJ Settlement Far Outstrips Net Profit

If approved, the settlement would set a new record for the pharmaceutical industry in its dealings with the federal government, but would be covered by the firm's existing reserves.

Senate Finance Committee Seeks Review Of Manufacturer Investigations By DOJ, HHS

Sen. Grassley requests briefings on the “scope and subject matter of all pending drug company investigations.” He is concerned that settlements like the Pfizer Neurontin deal are viewed as a cost of doing business.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS059282

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel